Get the Stockscreener App
2.08
2.83%
-0.04
After Hours:
2.07
-0.01
-0.48%
Pmgc Holdings Inc stock is traded at $2.08, with a volume of 68,948.
It is down -2.83% in the last 24 hours and down -10.04% over the past month.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
See More
Previous Close:
$2.12
Open:
$2.1
24h Volume:
68,948
Relative Volume:
0.11
Market Cap:
$2.87M
Revenue:
$2.45M
Net Income/Loss:
$-5.47M
P/E Ratio:
-0.0352
EPS:
-59.1634
Net Cash Flow:
$-6.05M
1W Performance:
-12.34%
1M Performance:
-10.04%
6M Performance:
+0.49%
1Y Performance:
-98.43%
1-Day Range:
$1.945
$2.19
1-Week Range:
$1.945
$2.41
52-Week Range:
$0.6273
$138.64
Pmgc Holdings Inc Stock (ELAB) Company Profile
Name
Pmgc Holdings Inc
Sector
Industry
Phone
888-445-4886
Address
120 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare ELAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELAB
Pmgc Holdings Inc
|
2.08 | 3.22M | 2.45M | -5.47M | -6.05M | -59.16 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.85 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.16 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
489.52 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Pmgc Holdings Inc Stock (ELAB) Latest News
Elevai Labs stock plunges to 52-week low of $2.09 amid steep decline - Investing.com Australia
Northstrive Biosciences completes phase I research on muscle-wasting treatment - Investing.com
NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Related Sarcopenia - GlobeNewswire
Northstrive Biosciences Amends License Agreement with MOA Life - TipRanks
PMGC Holdings Inc. Files Quarterly Report for Q1 2025, Highlights Strategic Growth Initiatives - Nasdaq
PMGC Holdings Inc. Announces Filing of Quarterly Report on Form 10-Q - The Manila Times
PMGC Holdings Expands into Hot GLP-1 Market While Pursuing Tech Acquisition: Q1 2025 Details Released - Stock Titan
PMGC Holdings Highlights Strong Capital Position: No Debt, Fully Funded, and Warrants Priced Above Market - ADVFN
PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. - GlobeNewswire
PMGC Capital Takes 5.09% Stake in Alaunos Therapeutics, Eyes Strategic Changes Including Fintech Expansion - Stock Titan
PMGC Holdings inks employee secondment deal with Northstrive By Investing.com - Investing.com Nigeria
PMGC Holdings inks employee secondment deal with Northstrive - Investing.com
Northstrive Biosciences Signs Binding Term Sheet with - GlobeNewswire
Northstrive Biosciences Signs Binding Term Sheet with Modulant Biosciences for Exclusive Global Animal Health Licensing of EL-22 - Stock Titan
PMGC Holdings Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance - ADVFN
PMGC Holdings Inc: Navigating Market Fluctuations with a 2.72M Market Cap - investchronicle.com
ELAB’s price-to-free cash flow ratio: How it affects investment decisions - uspostnews.com
PMGC Holdings (ELAB) Continues Uptrend During Pre-Hours On Positive Sentiment - Stocks Telegraph
ELAB Stock Price and Chart — NASDAQ:ELAB - TradingView
RESENDNorthstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health - GlobeNewswire
Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health - The Manila Times
Northstrive Biosciences Strengthens IP Portfolio with New - GlobeNewswire
Northstrive Expands Patent Portfolio: New GLP-1 Combo Treatment Could Prevent Muscle Loss in Obesity - Stock Titan
Northstrive Biosciences Co-Founder Featured on Bear Bull Traders Following Announcement of Positive FDA Response Supporting Submission of IND for EL-22 Phase 2 Clinical Trial - The Manila Times
Northstrive Biosciences Co-Founder Featured on Bear Bull - GlobeNewswire
Elevai Labs stock plunges to 52-week low of $2.22 amid steep decline - Investing.com India
Ratios Reveal: Breaking Down PMGC Holdings Inc (ELAB)’s Financial Health - DWinneX
ELAB’s Stock Journey: What Investors Need to Know About PMGC Holdings Inc’s Performance - investchronicle.com
Elevai Labs stock plunges to 52-week low of $2.22 amid steep decline By Investing.com - Investing.com South Africa
What is ELAB’s price-to-sales ratio telling us about the company’s value? - uspostnews.com
Northstrive Biosciences Announces Positive FDA Response Supporting A Submission of IND for a Phase 2 Clinical Trial for EL-22 in Combination with GLP-1 Receptor Agonist for Obesity Treatment - GlobeNewswire
Key deals this week: Vista Energy, PMGC Holdings, Colliers, John Wood and more - Seeking Alpha
PMGC Signs Letter of Intent to Purchase Custom IT Packaging Firm; Shares Fall - marketscreener.com
ELAB stock touches 52-week low at $2.51 amid steep annual decline - Investing.com
PMGC signs letter of intent to acquire U.S.-based custom IT packaging company - TipRanks
Pmgc Holdings Signs Letter Of Intent To Acquire Profitable U.S.-Based Custom It Packaging Company - MarketScreener
PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based Custom IT Packaging Company - GlobeNewswire
Strategic Acquisition: PMGC Eyes IT Packaging Leader Serving Major Data Centers - Stock Titan
PMGC’s Northstrive Biosciences signs partnership with Yuva Biosciences - TipRanks
PMGC Stock Surges After Subsidiary Inks Deal With Yuva Biosciences To Develop AI Led Therapies - Benzinga
ELAB Stock Soars: Buy Now Or Wait? - timothysykes.com
Northstrive Biosciences Signs Partnership with Yuva - GlobeNewswire
Elevai Labs stock plunges to 52-week low of $3.86 amid steep decline - Investing.com Australia
Elevai Labs stock plunges to 52-week low of $3.86 amid steep decline By Investing.com - Investing.com South Africa
PMGC Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - MarketScreener
PMGC Holdings Inc. Announces Filing of Annual Report on Form 10-K - The Manila Times
PMGC Holdings Targets Multiple Acquisitions to Accelerate Growth Strategy - Stock Titan
PMGC Holdings Inc. SEC 10-K Report - TradingView
PMGC subsidiary signs amended licensing agreement with MOA Life Plus - TipRanks
NorthStrive Biosciences Inc. Signs Amended Licensing Agreement with Existing Licensor, Aims to Capture Animal Health Market - GlobeNewswire
Pmgc Holdings Inc Stock (ELAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):